The Technical Analyst
Select Language :
Achilles Therapeutics plc [ACHL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Achilles Therapeutics plc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Achilles Therapeutics plc is listed at the  Exchange

0.83% $1.220

America/New_York / 28 mar 2024 @ 11:55


Achilles Therapeutics plc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 49.76 mill
EPS: -1.900
P/E: -0.640
Earnings Date: Mar 27, 2024
SharesOutstanding: 40.78 mill
Avg Daily Volume: 0.760 mill
RATING 2024-03-27
B+
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Neutral
DE: Neutral
P/E: Sell
Price To Book: Neutral
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.640 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.11x
Company: PE -0.640 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 1.082 - 1.358

( +/- 11.31%)
ATR Model: 14 days

Forecast: 13:34 - $1.216

Live Trading Signals (every 1 min)

Forecast 1: 12:04 - $1.227
Forecast 2: 12:54 - $1.220
Forecast 3: 13:34 - $1.216
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $1.220 (0.83% )
Volume 0.149 mill
Avg. Vol. 0.760 mill
% of Avg. Vol 19.58 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Achilles Therapeutics plc American Depositary Shares

Last 12 Months

Last 12 months chart data with high, low, open and close for Achilles Therapeutics plc American Depositary Shares

RSI

Intraday RSI14 chart for Achilles Therapeutics plc American Depositary Shares

Last 10 Buy & Sell Signals For ACHL

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Achilles Therapeutics plc American Depositary Shares

ACHL

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Last 10 Buy Signals

Date Signal @
XAUTUSDMar 28 - 11:57$2 210.88
TECHMar 28 - 11:57$70.16
TCOMMar 28 - 11:57CNY44.31
UMAUSDMar 28 - 11:55$4.10
^IBEXMar 28 - 11:37PTS11 089
TRIPMar 28 - 11:51$27.47
FUMOUSDMar 28 - 11:4910 000
VTRSMar 28 - 11:49$11.84
BGBUSDMar 28 - 11:471.029
PCARMar 28 - 11:47$123.94

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.